KML29 – Kodiac biolabs

Plain-language summaryIntrigue 48 / 100

KML29 is the second-generation cleanup of JZL184 from the same Cravatt laboratory, with about 4000-fold selectivity for MAGL over FAAH instead of the 300-fold of its predecessor. That extra cleanliness matters for research because it lets investigators raise endogenous 2-AG without simultaneously raising anandamide, isolating the contribution of each endocannabinoid. It is used purely as a research tool to study MAGL biology in pain, inflammation, and neurodegeneration, and has not been advanced to clinical trials. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundNiche research probe

50/100

Clean selective MAGL probe that solves JZL184’s FAAH crossover problem, confined to preclinical use

Look, KML29 is exactly what it says it is: a second-generation covalent MAGL inhibitor built to solve a specific problem that JZL184 created. The problem being FAAH crossover. JZL184 was a breakthrough when the Cravatt lab introduced it; suddenly investigators had a way to elevate 2-AG without disrupting the whole endocannabinoid system. But at only 300-fold MAGL/FAAH selectivity, any study using JZL184 at decent concentrations had to grapple with whether observed effects were genuinely MAGL-mediated or partly FAAH. Thats a real mechanistic headache, and it muddied a lot of otherwise well-designed preclinical work.

KML29 fixes that. The greater-than-4000-fold selectivity is a genuine improvement and it came from systematic medicinal chemistry out of the same Cravatt group (Niphakis et al., 2013). The carbamoylation mechanism targeting MAGL’s active-site serine is identical to JZL184; this isnt a novel mechanism, it’s a selectivity upgrade. The pharmacology is well characterized across rodent models: oral bioavailability, reasonable CNS penetration, and the irreversible binding means sustained MAGL suppression from a single dose, which suits certain experimental timelines. Selectivity profiling against other serine hydrolases is solid enough that it’s become a go-to tool when investigators need a clean readout.

What we like: the bench value is real. If you’re studying pain, neuroinflammation, or the specific contribution of 2-AG tone (as opposed to AEA and FAAH-derived signals), KML29 gives you a cleaner dissection instrument than anything else currently in the academic toolkit. Multiple groups have explicitly switched from JZL184 to KML29 to attribute effects to MAGL without the FAAH noise. In neuropathic pain models, neuroinflammation studies, and some neuropsychiatric work around anxiety and stress circuitry, KML29 has produced mechanistically interpretable results where JZL184 introduced ambiguity. That’s exactly what a good probe compound should do.

What we dont love: it’s a tool compound, full stop. No clinical development for KML29 itself exists, and the broader MAGL inhibitor pipeline (Abide/Lundbeck’s ABX-1431 in Tourette syndrome, for instance) uses entirely different scaffolds optimized for human PK. KML29 has done its job in the academic literature, and the field has mostly moved on to more indication-specific probes. The evidence base is multi-lab but preclinical only, and the endocannabinoid space is mature enough that deploying KML29 doesn’t generate the kind of foundational new knowledge it would have a decade ago.

Honestly, 50 reflects this profile exactly: genuine bench value in a well-defined niche, modest novelty for a compound that’s been in circulation since 2013, solid mechanistic rationale, and zero clinical translation signal. Worth having in the library for programs centered on endocannabinoid biology. Much less compelling if that isnt your research focus.

Novelty: 40
Mechanism promise: 55
In-category differentiation: 65
Evidence quality: 45
Translational signal: 30
Research bench value: 70

Rationale KML29 earns its score as a highly selective covalent MAGL tool that genuinely improves on JZL184’s FAAH crossover limitation; bench value is real and well-documented across multiple labs, but the compound has no clinical development pathway and the endocannabinoid field has largely moved to indication-specific probes.

Selective MAGL inhibitor (second-generation)

A second-generation covalent MAGL inhibitor with improved selectivity over FAAH.

Abstract

KML29 (CAS 1366507-82-3; molecular formula C27H24F4N2O4; molecular weight 516.49) is a second-generation covalent MAGL inhibitor developed by Cravatt and colleagues. The compound has improved selectivity for MAGL over FAAH (greater than 4000-fold) compared to JZL184 (300-fold), reducing the off-target FAAH inhibition that complicated interpretation of some JZL184 studies. Mechanism is the same as JZL184: irreversible carbamoylation of MAGL’s active-site serine. Used in academic research where clean MAGL inhibition without FAAH crossover is required. No human clinical development.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-331Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.